Trastuzumab biosimilar (BioXpress)

曲妥珠单抗生物类似药（BioXpress）

Report date: 2024/12/30 16:42:41

Base Information

Drug NameTrastuzumab biosimilar (BioXpress)
Drug Alias Name曲司珠单抗生物仿制药（BioXpress）Trastuzumabum biosimilar (BioXpress)群司珠单抗生物仿制药（BioXpress）曲妥珠单抗生物仿制药（BioXpress）BXT-2318 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBioxpress Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesBioxpress Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A